SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending due to recent policy moves aimed at driving down mortgage rates, which has ignited strong community optimism for a revitalized housing market. Investors are actively discussing the potential for increased transaction volume and a significant price appreciation, with many anticipating a move towards double-digit levels for the company's stock.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending following an FDA notification about deficiencies precluding labeling discussions for its Anaphylm drug, just weeks before its PDUFA date. While this news caused a significant stock drop, many in the community view it as an overreaction to minor "labeling semantics," asserting that the FDA would not engage in such detailed discussions if approval wasn't likely. The immediate focus is on how quickly these issues can be resolved for the potentially transformative needle-free epinephrine film, with the FDA confirming the review remains ongoing.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending amid extreme volatility and a significant price decline, with many in the community citing aggressive market 'manipulation' or 'fkkery'. Despite some expectations for a 'polar payday' driven by potential colder weather, the leveraged ETF faces relentless selling pressure, prompting discussions of capitulation, impending reverse splits, and its inherent decay as it tracks natural gas futures.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending after announcing a significant agreement with Meta to develop a 1.2-gigawatt power campus for AI data centers, driving conversation around the future of nuclear energy. This deal has ignited strong community debate over Oklo's speculative valuation, given its pre-revenue status, versus its long-term potential to address the escalating energy demands of the AI sector with advanced nuclear technology.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending as the market increasingly recognizes small modular reactors (SMRs) as a vital solution for the escalating energy demands of AI data centers. Community discussions highlight NuScale's unique position as the sole NRC-approved SMR technology, with recent positive developments like a Virginia energy award for a NuScale simulator and broader U.S.-Japan nuclear investment commitments fueling both investor interest and debates over long-term valuation and potential dilution.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is buzzing following significant new agreements to secure vast amounts of long-term nuclear energy, a critical move to power its rapidly expanding data centers and burgeoning AI infrastructure. This strategic embrace of clean, reliable power is driving community conversation, highlighting the increasing energy demands of hyperscalers and sparking diverse opinions on its financial implications and impact on the broader nuclear sector.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending due to a significant institutional investment, including a $1 billion stock and warrant sale priced above market, and its subsidiary Airobotics securing a prime contract for Israel's border security "Drone Hives" program. This has ignited strong community conviction, with many interpreting the premium paid and high warrant strike price as signals for substantial future appreciation in the autonomous defense sector, despite some discussions around short-term dilution.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Aptevo Therapeutics Inc

Aptevo Therapeutics (APVO) is trending following news of securing a $60 million equity line of credit, which some view as a critical funding boost for its pipeline while others fear it signals further dilution. The company's extremely low share float after a recent reverse split has ignited significant community discussion around a potential short squeeze, despite ongoing concerns about historical shareholder value and the nature of the new financing.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending after securing all regulatory approvals for its Renergen acquisition, which expands its portfolio into helium and LNG alongside its core isotope business. The community is actively discussing this, alongside a recent "Overweight" rating from Cantor Fitzgerald, as ASPI aims to be a critical supplier of HALEU and specialized isotopes for the growing nuclear and tech sectors.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings ($ANPA) is trending downwards, with community members discussing its potential delisting and comparing it to other Chinese-promoted stocks. Concerns about the company's thin float and potential manipulation are circulating, highlighted by J Capital Research's critical assessment. Some traders believe it's a bad short due to apparent whale support, while others anticipate a significant price drop.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ALT I had a lot of time to research yesterday and decided to learn a lot more about Durso and how his last transaction at Intercept went down and a massive peace and confidence came over me. I summarized my thoughts and shared them via email while flying home to a couple hundred of our ALT retail investors on here. I highly encourage all of you to also research the Intercept transaction and our retail shorts that might just be here for momentum.  
 
Jerry Durso initiated a competitive bid process for Intercept, (during a very non-advantageous time for Intercept based on FDA actions on their molecule) and was able to secure multiple bids after their bank solicited 19 interested parties. The bid winner also increased their final price by over $3 to $19 a share.  
 
This was a very short process as well.  
 
I doubt he will decide to make the process public (hopefully the rumors start coming out this weekend) but this process has most certainly already started for us. We have the goods now, we are not in a place of weakness and it is go time, end of Phase 2 for MASH and Obesity, Breakthrough Status granted and Phase 3 Trial Design with PathAI assisted biopsies as an Accelerated Approval endpoint.  
 
The calm and confidence I gained from learning about their auction process is understanding he will get a deal done, we all have fun debating lofty and realistic valuations but regardless, he is going to get one done and have multiple companies competing for Pemvi. I promise you the process has already started.  
 
Whether it is $2 billion or $5 billion is yet to be seen but either way, a transaction is coming and I hope they start signaling that big time publicly. It is also very strange right now we didn&#39;t post on social media our biggest catalyst ever and IR has gone completely dark on me and everyone else....Something is cooking. Get your hands on as many shares as you can, screw options.

The Machine

Keston Andrew

Wayside Sanford

paul roger

Maxim W

MJ Candlec

Ivan Larsson

Marv

Chris

Allen

Lynxtail

Blank Stocker

Jan Paul Beahm

Sett Mon Min

Greg

Paul Fisher

szrdz

VINCE_CARTER

CommonRyobiUser

Adam42

Scott Loftin

Littlebuylittle

Chardee MacDennis

Mary OReilly

Walter

Spoonie Spoon

Biotech And Real Estate

Roman Kudrin

$ALT I can&#39;t find anywhere (other than $ALT Pervi defensive posts) that $ALT will pursue Fibrosis Improvement as a trial endpoint in P3.  Furthermore, I haven&#39;t seen the scope of what $ALT ACTUALLY received Breakthrough Designation for.  I understand &quot;MASH&quot;, but is is solely MASH resolution or does it include other areas?   
 
I think for those Pervi&#39;s out there pumping $ALT, it would do you good to research what has actually happened and what hasn&#39;t.  And if your defense is that $ALT hasn&#39;t told you so you can&#39;t answer, then act on that...not pumping lies and misinformation.   
 
Can&#39;t wait to see this MASSIVE P3 trial design that&#39;s going to bleed money and bring $ALT shareholders further from profitability. 
 
Cheers!

StockTwits Web

The Legendary Mayor

$ALT I didn&#39;t get Britt&#39;s email, but I heard he confirmed $ALT is NOT pursuing Fibrosis in P3, only MASH and some NITs.   

Can anyone confirm this?

StockTwits For Android 

$ALT Where&#39;s the outrage on this board for this FUD and admitted LIE by @Diapers_Tequila?  @Wolly99 and @Designed2Gain, I expect , for your own integrity with the SEC (and to not add to the harrassment case against each of you for your threats and attacks against me), you will be reporting Britt for these fraudulent statements to the SEC.  Also, the 66 of you that hearted Britt&#39;s post are complicit in encouraging this fraudulent activity.  

Legal and Civil don&#39;t play favorites or emotions, they evaluate content.  That is where I am clear and win, and others stand to lose.  Social harrassment is not a victimless crime and increasingly frowned upon by regulatory agencies.

$ALT I keep seeing lazy FUDsters quoting Durso’s entire tenure at Intercept as the timeline it took him to get it sold.  That’s incorrect.  FDA rejected their MASH molecule Ocaliva in June 2023.  BO in September 2023.  
Facts matter. 🤓

StockTwits for iOS

Turribull

Altimmune Inc

 I had a lot of time to research yesterday and decided to learn a lot more about Durso and how his last transaction at Intercept went down and a massive peace and confidence came over me. I summarized my thoughts and shared them via email while flying home to a couple hundred of our ALT retail investors on here. I highly encourage all of you to also research the Intercept transaction and our retail shorts that might just be here for momentum.  
 
Jerry Durso initiated a competitive bid process for Intercept, (during a very non-advantageous time for Intercept based on FDA actions on their molecule) and was able to secure multiple bids after their bank solicited 19 interested parties. The bid winner also increased their final price by over $3 to $19 a share.  
 
This was a very short process as well.  
 
I doubt he will decide to make the process public (hopefully the rumors start coming out this weekend) but this process has most certainly already started for us. We have the goods now, we are not in a place of weakness and it is go time, end of Phase 2 for MASH and Obesity, Breakthrough Status granted and Phase 3 Trial Design with PathAI assisted biopsies as an Accelerated Approval endpoint.  
 
The calm and confidence I gained from learning about their auction process is understanding he will get a deal done, we all have fun debating lofty and realistic valuations but regardless, he is going to get one done and have multiple companies competing for Pemvi. I promise you the process has already started.  
 
Whether it is $2 billion or $5 billion is yet to be seen but either way, a transaction is coming and I hope they start signaling that big time publicly. It is also very strange right now we didn't post on social media our biggest catalyst ever and IR has gone completely dark on me and everyone else....Something is cooking. Get your hands on as many shares as you can, screw options.

Britt Peterson

Beer Good.

Corpkcots

@Diapers_Tequila you promise the process has already started? Wow thanks!! Do you have a timeframe whe it will be complete? I might go long then before the buyout

 you promise the process has already started? Wow thanks!! Do you have a timeframe whe it will be complete? I might go long then before the buyout

@Diapers_Tequila  
I didn’t receive your email(s)
Sent you my info awhile back. 
Can you check if you have me in the ALT contact list 
Thanks

  
I didn’t receive your email(s)
Sent you my info awhile back. 
Can you check if you have me in the ALT contact list 
Thanks

@Diapers_Tequila I like it. Curious why so against options as a play, if even not supplemental to shares. Given the relative confidence in a sure thing (of which over a reasonable timeline, say next 3-6 months) to which I agree, the calls are pretty attractive. Just curious.

 I like it. Curious why so against options as a play, if even not supplemental to shares. Given the relative confidence in a sure thing (of which over a reasonable timeline, say next 3-6 months) to which I agree, the calls are pretty attractive. Just curious.

jk1566

@Diapers_Tequila nothing against you or anything but you shouldnt make claims about know there will be a buyout or promising the process has started…because these things you dont know for sure and you are most likely wrong and theres gullible people on this board that will buy shares because of this post and most likey lose money

 nothing against you or anything but you shouldnt make claims about know there will be a buyout or promising the process has started…because these things you dont know for sure and you are most likely wrong and theres gullible people on this board that will buy shares because of this post and most likey lose money

@Diapers_Tequila 

Wow, great post DT… 🙏🙏🙏

Jimbo

@Diapers_Tequila I cannot fathom how this will be sold for 5b or less.

Would love some rumours to come out soon. That article yesterday was a nice step in the right direction.

Floyd

Dingus McKringleberry

Tom Snow

Justin Credible

 I cannot fathom how this will be sold for 5b or less.

Would love some rumours to come out soon. That article yesterday was a nice step in the right direction.

Benji596

@Blink182rulez I guess that is the risk of being on a message board for retail investors. You should head over to Orangebloods.com and check out the message boards  for college football portal movement and give those guys advice, they need it more than we do.

Patricia

Mr.Gayle Mack

Texas Longhorns fall 14-7 to Ohio State: Coach Sarkisian on Arch Manning's debut, red zone struggles, and key takeaways from the season opener.

Orangebloods

The Sunday Pulpit (via Loewy Law Firm): Perturbed? Sure. Panicked? Not yet

 I guess that is the risk of being on a message board for retail investors. You should head over to 

 and check out the message boards  for college football portal movement and give those guys advice, they need it more than we do.

@Diapers_Tequila They have raised substantial cash with their ATM IMO, on 12/19/25 and again on 1/6/26 which I estimate to be in the range of $75 M to $100 M, bringing their total cash to $325 to $375. I think this was a presequisite to the action you have projected; however, I feel very strongly that they will complete their discussions with the European Agencies and get full alignment on the PH3 protocal, and probably start File the protocal at clinicaltrials.com BEFORE they will do a deal with BP.  
 
Yes the negotiation is now ongoing. IMO, then now are giving access to the data to selected BP players with NDAs.  
 
Yes they can be entertaining some preliminary offers and deal sheets now.  
 
But there is NO WAY they will get their best deal until the BP can see exactly what the PH3 trial protocal will be.  
 
BP MUST know how many participants will be in the trial. BP MUST know alignment with the FDA on potential AA at 52 weeks. Only then, a maximum partnership deal can be reached, IMO.

brian duelfer

watsonturtle

Trialmed offers patient-focused clinical trials globally. Find a study, check your eligibility, and participate in cutting-edge medical research.

Trialmed

Global Clinical Trials & Research - Trialmed

 They have raised substantial cash with their ATM IMO, on 12/19/25 and again on 1/6/26 which I estimate to be in the range of $75 M to $100 M, bringing their total cash to $325 to $375. I think this was a presequisite to the action you have projected; however, I feel very strongly that they will complete their discussions with the European Agencies and get full alignment on the PH3 protocal, and probably start File the protocal at 

 BEFORE they will do a deal with BP.  
 
Yes the negotiation is now ongoing. IMO, then now are giving access to the data to selected BP players with NDAs.  
 
Yes they can be entertaining some preliminary offers and deal sheets now.  
 
But there is NO WAY they will get their best deal until the BP can see exactly what the PH3 trial protocal will be.  
 
BP MUST know how many participants will be in the trial. BP MUST know alignment with the FDA on potential AA at 52 weeks. Only then, a maximum partnership deal can be reached, IMO.

Ronald

@Blink182rulez Nothing against you or anything but we can tell you don&#39;t watch football.

robust8Billion

Patrick R.

Anthony

Markperk

Tee Bee

Diggs

7bilALTornothing

littlechj

Stew

Poksoloma

 Nothing against you or anything but we can tell you don't watch football.

@Diapers_Tequila  Flip Flop or Flip and Flop ?

Maxi Driver

@Diapers_Tequila 

Agreed, he’ll get the deal done, hopefully sooner rather than later.

And it sems Lee was quite responsive before, but has gone quiet on your end as well 🤔

 

Agreed, he’ll get the deal done, hopefully sooner rather than later.

And it sems Lee was quite responsive before, but has gone quiet on your end as well 🤔

FSDPSK

@Diapers_Tequila @Blink182rulez My thoughts  exactly;  and I’m a  girl!  🤷‍♀️😂

Robert Slovenz

 My thoughts  exactly;  and I’m a  girl!  🤷‍♀️😂

@FishStacker I had a few bounce back, send me another email at britt@texasonefund.org

 I had a few bounce back, send me another email at britt@texasonefund.org